Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

NanoValent Appoints Timothy Enns as Chief Executive Officer
  • USA - English


News provided by

NanoValent Pharmaceuticals, Inc

Jan 10, 2017, 19:50 ET

Share this article

Share toX

Share this article

Share toX


Los Angels, CA (PRWEB) January 10, 2017 -- NanoValent Pharmaceuticals, Inc., a development stage cancer focused pharmaceutical company, today announced the appointment of Timothy Enns as the company’s new Chief Executive Officer and President. In his role, Mr. Enns will be responsible for the execution of NanoValent’s business strategy which entails the development and commercialization of the company’s novel Hybrid Polymerized Liposomal Nanoparticle (HPLN) based Antibody-Drug Conjugate (ADC) therapeutics.

I am very excited to join the NanoValent team at this key moment in our progression and to help drive the successful development of the company’s novel anticancer agents and platform technology...

Post this

Prior to joining NanoValent, Mr. Enns held senior executive roles at KineMed Inc, Astex Pharmaceuticals, Inc (now Otsuka) and Sequus Pharmaceuticals (now JNJ) as well as senior positions at Trilex, Syncor, MGI Pharma and Upjohn (now Pfizer). Mr. Enns has a BS in Nutritional Science & Biochemistry from UC Davis.

With more than 30 years of experience in leadership roles spanning large pharmaceutical and early development stage, venture backed biopharmaceutical companies, Mr. Enns brings broad expertise from discovery through commercialization. "Having now achieved the scientific validation of our platform technology, possessing truly experienced and dynamic people in our leadership team is going to be vital to our success and I’m convinced that Tim’s arrival is an important step in that direction,” said Jon Nagy, Ph.D., Chief Scientific Officer and co-founder of NanoValent Pharmaceuticals.

"I am very excited to join the NanoValent team at this key moment in our progression and to help drive the successful development of the company’s novel anticancer agents and platform technology," Mr. Enns said. "With a highly experienced and balanced core management team and a well-defined vision I’m convinced that NanoValent is very well positioned to advance its highly differentiated ADC therapeutics very rapidly,” he added.

“While existing chemotherapeutic agents are effective against many kinds of cancers, for relapsed patients such as individuals with Ewing sarcoma, the survival rate has not improved in 30 years. NanoValent’s approach via HPLN ADCs is able to vastly increase the potency of current and emerging therapies and has the potential to make a dramatic difference in the survival outcome for these patients,” said Dr. Timothy Triche, Co-Director of the Center for Personalized Medicine at Children’s Hospital Los Angeles and Chief Medical Officer and co-founder of NanoValent Pharmaceuticals.

“Once initially clinically validated in Ewing Sarcoma, NanoValent will also be able to progress further candidates," added Mark Lewis, Chief Operating Officer, “Due, we believe, to the greater flexibility, efficiency and specificity our HPLN approach seemingly allows versus other comparable approaches, either in market or in development. We have already validated our HPLNs with small molecule chemotherapeutics, nucleic acids, and even plasmids containing the entire CRISPR/Cas9 assembly for gene editing. Therefore, although our own leading candidates are initially focused on application in pediatric oncology, they also have broader capability and we also hope very soon to be validating overall regulatory and clinical pathways for many other candidates, in general oncology as well as other therapeutic areas.”

The NanoValent executive team will be in San Francisco during J.P. Morgan 35th Annual Healthcare Conference commencing January 9th, meeting with potential pharmaceuticals partners and investors and is also scheduled to present at BioTech Showcase on Jan 11th. Please contact Mr. Lewis directly for more information.

About NanoValent Pharmaceuticals, Inc.
NanoValent Pharmaceuticals, Inc., founded in 2010, is a privately-held company focused on the development and commercialization of a new generation, nanoparticle based, antibody-drug conjugate (ADC) technology as well as novel anticancer agents based on the company’s proprietary Hybrid Polymerized Liposomal Nanoparticles (HPLN) core technology. So far working in close collaboration with Children’s Hospital Los Angeles (CHLA), NanoValent aims to provide greater flexibility and choice for patients restricted by current treatment options by repositioning existing therapies as well as optimizing the delivery of emerging drug candidates.

The company’s proprietary platform technology, subject to broad patent control, is an important, new, effective and safe drug delivery vehicle comprising a uniquely designed nanoparticle, with an encapsulated drug of choice, linked to various targeting specific, tumor-associated, monoclonal antibodies. Due to this flexibility of drug delivery and targeting NanoValent’s innovative, proprietary, platform technology can be easily used with various therapeutic or diagnostic agents whose potential are restricted due to issues such as suboptimal targeting or unacceptable toxicities. NanoValent’s leading drug candidates, including NV101 (Dox-anti-CD99), NV102 (Dox-anti-CD19) and NV103 (Irinotecan-anti-CD99), are approaching phase I clinical trials with initial validating programs including Ewing Sarcoma. Further development programs with NV102 in Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) are expected to begin in 2018.

Visit http://www.nanovalent.com for more information.

Mark Lewis, NanoValent Pharmaceuticals, Inc, http://www.nanovalent.com, +1 +1 480 324 6932, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.